Quanterix (QTRX) Stock Price, News & Analysis

Company Overview

Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops technologies for detecting and measuring very low concentrations of biomarkers in blood and other biological samples. Its platform is designed to support research and clinical development in areas including neurology, oncology, immunology, infectious diseases and cardiovascular disease.

The company’s core technology, Simoa (Single Molecule Array), uses digital immunoassay methods to detect proteins and other biomarkers at levels below the practical range of many conventional laboratory tests. Quanterix offers laboratory instruments such as the HD-X, SR-X and SP-X systems, along with assay kits, consumables, software and related laboratory services. Its products are used by pharmaceutical and biotechnology companies, academic and government researchers, diagnostic developers and clinical laboratories.

Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix serves customers through direct and commercial channels in the United States and internationally. The company has also expanded its offerings through partnerships and acquisitions, including the addition of technologies intended to broaden its biomarker analysis capabilities. Masoud Toloue has served as Quanterix’s president and chief executive officer since January 2024.

Key Stats

• Today's Range: $3.62 to $3.90
• 50-Day Range: $2.42 to $4.03
• 52-Week Range: $2.15 to $8.77
• Volume: 1.03 million shs
• Average Volume: 908,085 shs
• Market Capitalization: $180.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Reduce

Quanterix Stock Analysis - MarketRank™

Quanterix scored higher than 19% of companies evaluated by MarketBeat, and ranked 843rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Quanterix has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Quanterix has a consensus price target of $3.00, representing about 21.3% downside from its current price of $3.81.

Amount of Analyst Coverage

Quanterix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Quanterix is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quanterix is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quanterix has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.68% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 4.23.

Change versus previous month

Short interest in Quanterix has recently increased by 3.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quanterix does not currently pay a dividend.

Dividend Growth

Quanterix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: N/A

News Sentiment

Quanterix has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

Search Interest

1 people have searched for QTRX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Quanterix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quanterix insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Quanterix is held by insiders.

Percentage Held by Institutions

86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:QTRX
• CIK: 1503274
• Web: www.quanterix.com
• Phone: (617) 301-9400
• Fax: N/A
• Employees: 450
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Quanterix: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: -21.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.15 million
• Net Margins: -80.25%
• Pretax Margin: -81.68%
• Return on Equity: -26.09%
• Return on Assets: -19.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.40
• Quick Ratio: 2.45

Sales & Book Value

• Annual Sales: $153.17 million
• Price / Sales: 1.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.33 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 47,293,000
• Free Float: 46,584,000
• Market Cap: $180.19 million
• Optionable: Optionable
• Beta: 1.02